R
Ruud Delwel
Researcher at Erasmus University Medical Center
Publications - 210
Citations - 19907
Ruud Delwel is an academic researcher from Erasmus University Medical Center. The author has contributed to research in topics: Myeloid leukemia & Leukemia. The author has an hindex of 66, co-authored 203 publications receiving 18168 citations. Previous affiliations of Ruud Delwel include University of Rome Tor Vergata & Erasmus University Rotterdam.
Papers
More filters
Journal ArticleDOI
Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation.
Maria E. Figueroa,Omar Abdel-Wahab,Chao Lu,Patrick S. Ward,Jay P. Patel,Alan Shih,Yushan Li,Neha Bhagwat,Aparna Vasanthakumar,Hugo F. Fernandez,Martin S. Tallman,Zhuoxin Sun,Kristy L. Wolniak,Justine K. Peeters,Wei Liu,Sung E. Choe,Valeria Fantin,Elisabeth Paietta,Bob Löwenberg,Jonathan D. Licht,Lucy A. Godley,Ruud Delwel,Peter J. M. Valk,Craig B. Thompson,Ross L. Levine,Ari Melnick +25 more
TL;DR: Mutational and epigenetic profiling of a large acute myeloid leukemia (AML) patient cohort revealed that IDH1/2-mutant AMLs display global DNA hypermethylation and a specificHypermethylation signature, suggesting a shared proleukemogenic effect.
Journal ArticleDOI
Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia
Mark A. Dawson,Rab K. Prinjha,Antje Dittmann,George Giotopoulos,Marcus Bantscheff,Wai-In Chan,Samuel Robson,Chun-wa Chung,Carsten Hopf,Mikhail M. Savitski,Carola Huthmacher,Emma Gudgin,Dave Lugo,Soren Beinke,Trevor D. Chapman,Emma J. Roberts,Peter Ernest Soden,Kurt R. Auger,Olivier Mirguet,Konstanze Doehner,Ruud Delwel,Alan Kenneth Burnett,Phillip Jeffrey,Gerard Drewes,Kevin Lee,Brian J. P. Huntly,Tony Kouzarides +26 more
TL;DR: It is shown that a novel small molecule inhibitor of the BET family, GSK1210151A (I-BET151), has profound efficacy against human and murine MLL-fusion leukaemic cell lines, through the induction of early cell cycle arrest and apoptosis, establishing the displacement of BET proteins from chromatin as a promising epigenetic therapy for these aggressive leukaemias.
Journal ArticleDOI
Prognostically useful gene-expression profiles in acute myeloid leukemia.
Peter J. M. Valk,Roel G.W. Verhaak,M. Antoinette Beijen,Claudia Erpelinck,Sahar Barjesteh van Waalwijk van Doorn-Khosrovani,Judith M. Boer,H. Berna Beverloo,Michael Moorhouse,Peter J. van der Spek,Bob Löwenberg,Ruud Delwel +10 more
TL;DR: Gene-expression profiling allows a comprehensive classification of AML that includes previously identified genetically defined subgroups and a novel cluster with an adverse prognosis.
Journal ArticleDOI
DNA Methylation Signatures Identify Biologically Distinct Subtypes in Acute Myeloid Leukemia
Maria E. Figueroa,Sanne Lugthart,Yushan Li,Claudia A.J. Erpelinck-Verschueren,Xutao Deng,Paul J. Christos,Elizabeth D. Schifano,James G. Booth,Wim H. van der Putten,Lucy Skrabanek,Fabien Campagne,Madhu Mazumdar,John M. Greally,Peter J. M. Valk,Bob Löwenberg,Ruud Delwel,Ari Melnick +16 more
TL;DR: DNA methylation profiles segregated patients with CEBPA aberrations from other subtypes of leukemia, defined four epigenetically distinct forms of AML with NPM1 mutations, and showed that established AML1-ETO, CBFb-MYH11, and PML-RARA leukemia entities are associated with specific methylation profile.
Journal ArticleDOI
Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): Association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance
Roel G. W. Verhaak,Chantal S. Goudswaard,Wim H. van der Putten,Maarten A. Bijl,Mathijs A. Sanders,Wendy Hugens,André G. Uitterlinden,Claudia Erpelinck,Ruud Delwel,Bob Löwenberg,Peter J. M. Valk +10 more
TL;DR: It is demonstrated that patients with intermediate cytogenetic risk AML without FLT3 ITD mutations but with NPM1 mutations have a significantly better overall survival (OS) and event-free survival (EFS) than those without N PM1 mutations.